Granturi depuse
Start-Up Nation 2017
Dosar nr. 3840 – Proteza de brat activa – ARCIRE APPLIED SCIENCE SRL-D
Produsul de baza al societatii, o proteza activa, avand un grad inalt de complexitate, necesita utilizarea unor tehnologii avansate de productie. Realizarea structurii de rezistenta si a gemetriei protezei se bazeaza pe o metoda revolutionara de realizare a structurilor solide prin depuneri strat cu strat prin procedeul de stereolitografie.
Software-ul achiztionat si unitatea PC asigura capacitatea de simulare privind studiul de rezistenta mecanica, termica si electrica dar permite si transformarea geometriei tridimensionale a volumului in coordonate pentru imprimanta 3D sau pentru masina de aschiat cu control numeric. Senzorii mioelectrici cat si placile de achizitie de date permit achizitia semnalului electic generat de muschi fara a fi nevoie de o interventie chirurgicala si transformarea acestuia in comenzi de control a unor actuatori electromagnetici liniari ce pun in miscare bratul, respectiv degetele acestuia. Aparatul de scanare optica tridimensionala asigura masurarea fara contact de precizie a dimensiunilor bratului pacientului si transformarea acestuia intr-un model virtual ce permite confectionarea protezei cu dimensiuni personalizate. Masina de recilcat plastice ne permite sa procuram materia prima prin recilarea diferitor mase plastice si astfel sa reducem costul protezei. Aparatul de injectie mase plastice accelereaza productia de serie prin injectia materialellor plastice in matrite confectionate cu ajutorul masinii de aschiere cu comanda numerica pentru realizarea componentelor protezei. Pentru situatii deosebite in care
bratul lipseste complet, interprinzatorul isi propune sa elaboreze un sistem de actionare pe baza masuratorii semnalelor electroecelfalografice (EEG) folosind o casca portabila disponibila in comert la un pret accesibil.
In faza de cercetare-dezvoltare a prototipului se vor folosi diferite echipamente pentru a indetifica experiemental parametrii electrici necesari functioanrii in conditii optime a actuatorilor: fazmetru, wattmetru digital cu senzor sara fir, clema ampermetrica, gausmetru, osciloscop, multimetru, sursa de putere reglabila, accelerometru, senzor de
masurat forta.
Towards safer and more efficient cancer therapy: local augmentation of the levels of reactive oxygen species via the plasmon effect, using irradiated and radiolabeled gold nanoparticles
Acronym: GOLDROS
EEA/NO Research Programme:: NO Grants RO-NO-2019
Partners
IFE
TUIASI
https://www.eeagrants.ro/en/programme/research
Project Thematic Area
Main Key Topic: C. 7. Developing patient-centred strategies to fight cancer;
Key Topic 2: F.3. Biotechnology for health, medicine and related industries;
Keywords
-
cancer
-
radiosensitizers
-
plasmonic nanostructures
-
nanobiotechnology
-
radionuclides
The key objective in cancer radiotherapy is to increase therapeutic efficacy by maximizing damage to the tumor cells while reducing lesions caused in the healthy tissue. The current limitations of conventional external beam radiotherapy (EBRT) are related to the fact that not all tumor cells can receive the same lethal dose of radiation. To get more radiotherapy into each cell, an alternative treatment approach was considered through internal radionuclides therapy, in which internal radioisotopes are delivered into tumors. Thus, it has been achieved a significant improvement in the results for internal radionuclide therapy in comparison to EBRT.
Radioisotopes have the advantage of emitting Auger electrons that perform energy transfer at the decay site (tumor cells), the number of affected surrounding healthy cells being negligible, thus ensuring low toxicity of radioactivity. Since the effectiveness with radioisotopes treatment depends on the number of emitted electrons, nanoparticles (with a large atomic number) can be labeled with various radioisotopes, for the increase of locally induced radiation. However, it has been observed that the effect of radio-enhancement depends on increasing the density of isotopic-marked nanoparticles.
We propose a new way of radio-enhancement using the tendency to increase the density of plasmonic nanoparticles (Gold) as a result of exposure to different wavelengths in the visible spectrum. Shrinking the distance between irradiated nanoparticles and marked with isotopes, may improve the radiation initiated by the secondary electrons. Our previous studies have shown that irradiation in certain wavelengths of gold nanoparticles has led to increased levels of reactive oxygen species (ROS) in cancer cells, but have not harmed the surrounding healthy cells. The activity of lowering the metabolism of cancer cell caused by irradiated gold nanoparticles and labeled with isotopes can be evaluated by using Positron-emission tomography (PET) technology to trace a single particle (PEPT), separated using a microfluidic device.These assessments will be used to calculate the dose rate of the Auger electron emitters.
Reactive Oxygen Species mediated cancer Treatment Assay with Synthesized Theranostic Irradiated nanoConjugate
Programme H2020 Apel H2020-FETOPEN-2018-2019-2020-01 RIA ID 964645 Acronim ROS-TASTIC 03/06/2020
Discipline: Medical biotechnology
Subdiscipline: Technologies involving the manipulation of cells, tissues, organs or the
whole organism
Descriptor: Biomaterial engineering
Precision oncology; Theranostic nanoconjugate; Liquid biopsy; Microfluidic diagnosis platform;
Targeted drug delivery; Drug discovery
Partners
SC. ARCIRE APPLIED SCIENCE SRLD – Romania
INSTITUTT FOR ENERGITEKNIKK – Norway
UNIWERSYTET MEDYCZNY W BIALYMSTOKU – PL
LABORATORIO IBERICO INTERNACIONAL DE NANOTECNOLOGIA – PT
MEDIZINISCHE UNIVERSITAET WIEN -AT
SIKEMIA- FR
INSTITUTUL NATIONAL DE CERCETAREDEZVOLTARE PENTRU MICROTEHNOLOGIE -RO
LACONSEIL -Belgium
ROS-TASTIC is a highly innovative project aimed at developing and testing the efficiency of cancer drugs transported by an active redox nanocarrier into circulating tumor cells using a microfluidic platform.
This cutting-edge strategy aims to develop 1) a plasmonic gold nanoparticle functionalized with Onion-like Carbons nanocarrier as a drug carrier able to enhance reactive oxygen species (ROS) levels in cancer cells after local activation with low-energy irradiation in visible light, and 2) a microfluidic device to extract viable cancer cells from patients’ blood, e.g., liquid biopsy.
Our approach is to generate precisely controlled ROS using nanoparticles at very low concentrations to stimulate redox perturbation to destroy cancer cells with nanoparticle plasmon resonance induced by photoactivity and then to test the effect of drugs loaded on the nanocarrier on cancer cells with our novel microfluidic platform.
To achieve our goals, our multidisciplinary consortium with expertise in nanotechnology, applied chemistry, materials engineering, sensor manufacturing, and biology will produce plasmonic nanoconjugates to control the redox perturbation in cells by plasmonic stimulation; analyze its efficiency and toxicity in vitro and in vivo; create and evaluate a microfluidic platform for cell extraction; test the drug-nanocarrier efficacy and active redox effect of the nanocarrier on liquid biopsy, and validate the microfluidic platform and nanocarrier in pre-clinical trials.
This beyond the state-of-the-art project will create a novel drug nanocarrier with redox-active properties and microfluidic platform for drug testing with the potential to produce a mobile mini-lab diagnostic tool designed to meet the urgent need for low-cost mobile technologies for personalized cancer therapies. The project proposal contributes to the development of new active drug delivery systems and new tools and services able to integrate optimal therapeutic solutions for cancer patients.
Reactive Oxygen Species mediated cancer Treatment Assay with Synthesized Theranostic Irradiated
nanoConjugate
Programme HORIZON-EIC-2021-PATHFINDEROPEN-01 HORIZON-EIC 101046647 ROS-TASTIC 25/05/2021
Discipline: Medical biotechnology
Subdiscipline: Technologies involving the manipulation of cells, tissues, organs or the whole
organism
Descriptor: Biomedical engineering
https://eismea.ec.europa.eu/funding-opportunities/calls-proposals/eic-pathfinder-open-2021_en
Partners
SC. ARCIRE APPLIED SCIENCE SRLD – Romania
INSTITUTUL NATIONAL DE CERCETAREDEZVOLTARE PENTRU MICROTEHNOLOGIE -Romania
SIKEMIA – France
MEDIZINISCHE UNIVERSITAET WIEN – Austria
UNIWERSYTET MEDYCZNY W BIALYMSTOKU – Poland
INSTITUTT FOR ENERGITEKNIKK – Norway
LACONSEIL – Belgium
Oxidative stress can be viewed by our body as a friend or as an enemy. It can cause premature death in cells stressed by toxins and lack of oxygen OR it can help the body identify affected and dysfunctional cells by eliminating them and replacing them with new ones. The difference between death and healing is given by the level of oxidative stress generated. Addressing the problem of cancer from the perspective of modulating the level of stress tolerated by each patient can be considered a new direction of research. Our vision is to support and stimulate the natural healing processes of cancer patients through innovative home treatment. We will develop a portable platform for screening, therapy, and monitoring of cancer evolution used in at-home treatment. This triple therapeutic agent takes advantage of the synergistic effect between therapeutic molecule, ROS generator therapy and ROS Signaling, which holds the possibility of unbounded potential to change the current perspective in cancer treatment. The nanoconjugate based on gold nanoparticle preactivated by photoirradiation and Onion-like Carbons nanoparticles, will allow a precise balance of ROS generation in tissue, damaging only the cancer cells while stimulating viability of healthy cells and the body’s natural defense mechanism. The platform allows monitoring and evaluating the state of trapped CTCs from blood. It distinguishes between different types of tumor cells by measuring their electrical properties which will be recorded in a digital database of electrical signatures for each type of CTCs. It allows a digital identification of each CTC type using an innovative GFET sensor, a nanocrystalline graphite-based
field effect transistor, functionalized with gold nanoparticles, a cross-linker and biomarker for specific antibodies. Breast cancer biomarkers holds prognostic, predictive, and pharmacodynamic properties making the device a powerful tool for choosing and evaluating a particular treatment option.
Creating a Reactive Oxygen Species mediated cancer Therapy Assay with Synthesized Targeted Irradiated nanoCarrier
HORIZON HORIZON-EIC-2022-PATHFINDEROPEN-01 HORIZON-EIC 101099677 ROS-TASTIC Final 04/05/2022
Discipline: Medical biotechnology
Subdiscipline: Technologies involving the manipulation of cells, tissues, organs or the whole
organism
Descriptor: Biomedical engineering
Free keywords: cancer diagnosis/treatment, nanocarrier, ROS induced therapy, mobile microfluidic platform/cartridge, circulating
cancer cell, isolation and analysis CTCs, dielectrical signature, EIS/GFET sensor
Parteners
INSTITUTUL NATIONAL DE CERCETAREDEZVOLTARE PENTRU MICROTEHNOLOGIE – RO
SC. ARCIRE APPLIED SCIENCE SRLD- RO
UNIWERSYTET MEDYCZNY W BIALYMSTOKU – PL
MEDIZINISCHE UNIVERSITAET WIEN – AT
LACONSEIL – BE
SIKEMIA – FR
INSTITUTT FOR ENERGITEKNIKK – NO
The power of precision medicine to match treatments for each patient is evident as each cancer patient requires individual complicated treatment decisions. ROS-TASTIC is a mobile microfluidic platform that introduces a novel approach to the treatment of breast cancer (BC). Our main aim is to develop a revolutionary at-home, inexpensive Lab-on-a-Chip device with Point-of-Care applicability for effective and efficient screening, diagnosis, and personalized BC therapy. Our approach is to isolate circulating cancer cells (CTCs) from a liquid biopsy, to test the efficacy of the therapy based on the targeted delivery of plasmon-driven reactive oxygen species (ROS), using interchangeable disposable microfluidic cartridges that will help diagnose the tumor type using predictive and pharmacodynamic evaluations. This microfluidic device will sample CTCs and characterize them by electrochemical impedance spectroscopy. The CTCs immobilized will then be incubated with a nanocarrier based on gold nanoparticles (AuNPs) loaded with targeted estrogen receptor modulators selected from a built-in BC treatment database in the platform. The survival or death response of CTCs will show whether the type of molecule released by the photoactivated nanocarrier can provide effective therapy within the tumor and metastases. Moreover, the nanocarrier based on photo-activated AuNPs coated with a carbon allotrope (Onion-like Carbon) can produce a controlled increase of ROS level in the tissue that will specifically kill tumor cells using the body’s own natural defense. Our team of scientists has all the expertise necessary to develop this complete platform for early cancer detection, personalized therapy, real-time monitoring, and prediction of recurrence and prognosis. This at-home approach has transformative potential in personalized BC therapy by individualizing the treatment, shortening investigation time, eliminating outpatient testing costs, and monitoring disease evolution and drug effect.
Novel nanoparticle carrier-based targeted inhaled immunotherapy for steroid-resistant asthma
HORIZON HORIZON-HLTH-2022-DISEASE-06-two-stage HORIZON-RIA 101080842 Cellectomy Final 17/05/2022
Biochemistry and molecular biology
Keywords: Steroid-resistant asthma, chronic inflammation, inhaled allergen-specific immunotherapy, immunomodulation, bispecific fusion protein, in vivo models, clinical cohort, barcode lipid NPs, Gold NPs
Partners
MEDIZINISCHE UNIVERSITAET WIEN – AT
PROMOSCIENCE SRL- IT
MOVERIM CONSULTING SPRL – BE
MIGAL GALILEE RESEARCH INSTITUTE LTD -Israel
TEL AVIV UNIVERSITY – IL
Srebrnjak Children’s Hospital – HR
SC. ARCIRE APPLIED SCIENCE SRLD – Romania
BIOEMISSION TECHNOLOGY SOLUTIONS IKE – EL
ASPHALION SL- ES
Barcode Diagnostics LTD -Israel
UNIVERSITAT WIEN – AT
Asthma is a significant non-communicable chronic disease that affects approximately 300 million people worldwide with an increasing prevalence. About 5-10% of patients have severe uncontrolled steroid-resistant asthma (SA) resulting in hospitalization, high health care costs, personal costs, and deaths, and constitutes a profound unmet medical need. Cellectomy’s highly interdisciplinary team of experts aims to develop an innovative next-generation inhaled immunotherapy (IMT) to treat SA, targeting the pathogenic lung inflammatory cells that cause chronic disease and eventual lung damage. Cellectomy will tackle SA using cutting-edge technologies to design, produce and test in vitro and in vivo efficacy and preliminary safety. Together with an adolescent SA cohort, we plan to elucidate disease mechanisms, discover new biomarkers and determine mode of action of this novel IMT consisting of 1) nanoparticle carriers (NPCs) made of either gold (Au)NPs or state-of-the-art barcoded lipid NPs functionalized, 2) with a novel bispecific CTLA4-PD-1 fusion protein, 3) a novel sphingosine-competitive immunomodulator to downregulate and disperse the chronic inflammatory microenvironment containing resident macrophages and memory T cells, and 4) personalized with added specific allergen. Cellectomy’s ground-breaking strategy positioned at ‘idea to application’ will be achieved within 4-years and provide IMT for SA treatment and prevention. The NPCs will be a personalized and affordable off-the-shelf product with wide potential application to other chronic inflammatory and immune-mediated diseases. It will address patient needs, reduce the health care system and patient burden, reduce economic loss (DALY) and increase life quality. Our strategic approach will reach the proof of concept stage for Europe and will allow us to transfer the IPR to the European Producing Sector and leverage for new investments from Biotech and Pharma.
